KFDA to Request Additional Data on Hanmi's Anti-Obesity Drug

According to an industry source, the Korea Food and Drug Administration (KFDA) is to request Hanmi Pharmaceuticals to make an additional data provision for its anti-obesity drug Slimer (active ingredient: sibutramine mesylate), which was originally submitted for approval in December of last year.

Hanmi's request for Slimer was made during the drug re-examination period that is designated for...